TY - JOUR
T1 - Expanding TREC and KREC Utility in Primary Immunodeficiency Diseases Diagnosis
AU - Korsunskiy, Ilya
AU - Blyuss, Oleg
AU - Gordukova, Maria
AU - Davydova, Nataliia
AU - Zaikin, Alexey
AU - Zinovieva, Nataliia
AU - Zimin, Sergey
AU - Molchanov, Robert
AU - Salpagarova, Aminat
AU - Filipenko, Maxim
AU - Eremeeva, Alina
AU - Prodeus, Andrey
AU - Korsunskiy, Anatoliy
AU - Hsu, Peter
AU - Munblit, Daniel
N1 - Copyright © 2020 Korsunskiy, Blyuss, Gordukova, Davydova, Zaikin, Zinovieva, Zimin, Molchanov, Salpagarova, Eremeeva, Filipenko, Prodeus, Korsunskiy, Hsu and Munblit.
PY - 2020/3/3
Y1 - 2020/3/3
N2 - Primary immunodeficiency diseases (PID) area heterogeneous group of disorders caused by genetic defects of the immune system, which manifest clinically as recurrent infections, autoimmune diseases or malignancies. Early detection of PID remains a challenge, particularly in older children with milder and less specific symptoms. This study aimed to assess TREC and KREC diagnostic ability in PID. Data from children assessed by clinical immunologists at Speransky Children's Hospital, Moscow, Russia with suspected immunodeficiencies were analyzed between May 2013 and August 2016. Peripheral blood samples were sent for TREC/KREC, flow cytometry (CD3, CD4, CD8 and CD19), IgA and IgG analysis. A total of 434 children [189 healthy, 97 with group I and II PID (combined T and B cell immunodeficiencies & well-defined syndromes with immunodeficiency) and 148 group III PID (predominantly antibody deficiencies)] were included. Area under the curve (AUC) for TREC in PID groups I and II diagnosis reached 0.82 (CI = 0.75-0.90), with best model providing sensitivity of 65% and specificity of 92%. Neither TREC, nor KREC had added value in PID group III diagnosis. In this study, the predictive value of TREC and KREC in PID diagnosis was examined. We found that the TREC had some diagnostic utility for groups I and II PID. Possibly, addition of TREC measurements to existing clinical diagnostic algorithms may improve their predictive value. Further investigations on a larger cohort are needed to evaluate TREC/KREC abilities to be used as diagnostic tools on a wider scale.
AB - Primary immunodeficiency diseases (PID) area heterogeneous group of disorders caused by genetic defects of the immune system, which manifest clinically as recurrent infections, autoimmune diseases or malignancies. Early detection of PID remains a challenge, particularly in older children with milder and less specific symptoms. This study aimed to assess TREC and KREC diagnostic ability in PID. Data from children assessed by clinical immunologists at Speransky Children's Hospital, Moscow, Russia with suspected immunodeficiencies were analyzed between May 2013 and August 2016. Peripheral blood samples were sent for TREC/KREC, flow cytometry (CD3, CD4, CD8 and CD19), IgA and IgG analysis. A total of 434 children [189 healthy, 97 with group I and II PID (combined T and B cell immunodeficiencies & well-defined syndromes with immunodeficiency) and 148 group III PID (predominantly antibody deficiencies)] were included. Area under the curve (AUC) for TREC in PID groups I and II diagnosis reached 0.82 (CI = 0.75-0.90), with best model providing sensitivity of 65% and specificity of 92%. Neither TREC, nor KREC had added value in PID group III diagnosis. In this study, the predictive value of TREC and KREC in PID diagnosis was examined. We found that the TREC had some diagnostic utility for groups I and II PID. Possibly, addition of TREC measurements to existing clinical diagnostic algorithms may improve their predictive value. Further investigations on a larger cohort are needed to evaluate TREC/KREC abilities to be used as diagnostic tools on a wider scale.
KW - KREC
KW - PID
KW - TREC
KW - primary immunodeficiency diseases
KW - primary immunodeficiency diseases diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85082052503&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2020.00320
DO - 10.3389/fimmu.2020.00320
M3 - Article
C2 - 32194560
SN - 1664-3224
VL - 11
SP - 320
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 320
ER -